Eva Wesley, Author at Born2Invest

Eva Wesley

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.

Born2Invest uses cookies in order to improve your experience and make further customizations to how we present our content. By continuing to use our website, you accept and give your consent to our practices as described in the following: our revised Privacy Policy, Cookie Policy, and Terms of Use.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Born2Invest

Eva Wesley

Stories By Eva Wesley

Atrys Doubles Losses to 45 Million in 2023, but Increases Income by 27.3%

Faes Farma Plans to Grow by Double Digits in Latin America

Cure51 Raises 15 Million Euros in a Round Led by Sofinnova Partners

Ysios Capital Invests in Engrail Therapeutics’ $157 Million Series B

Europacific Growth Fund Lends Over 100 Million Euros in Grifols Shares

MDMA: US Biotech Industry is Breaking the Next Drug Taboo

AstraZeneca Will Invest 1.3 Billion until 2027 in Catalonia

BlackRock, Capital Research and Jefferies Lend 170 Million Euros in Grifols Shares

Almirall and Eloxx Sign an Exclusive Licensing Agreement for Rare Dermatological Pathologies

AstraZeneca and Wivi Vision Receive the Bioèxit Prize from CataloniaBio